The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK.
Hum Mol Genet. 2012 Oct 15;21(R1):R37-44. doi: 10.1093/hmg/dds362. Epub 2012 Sep 8.
Patients with developmental disorders often harbour sub-microscopic deletions or duplications that lead to a disruption of normal gene expression or perturbation in the copy number of dosage-sensitive genes. Clinical interpretation for such patients in isolation is hindered by the rarity and novelty of such disorders. The DECIPHER project (https://decipher.sanger.ac.uk) was established in 2004 as an accessible online repository of genomic and associated phenotypic data with the primary goal of aiding the clinical interpretation of rare copy-number variants (CNVs). DECIPHER integrates information from a variety of bioinformatics resources and uses visualization tools to identify potential disease genes within a CNV. A two-tier access system permits clinicians and clinical scientists to maintain confidential linked anonymous records of phenotypes and CNVs for their patients that, with informed consent, can subsequently be shared with the wider clinical genetics and research communities. Advances in next-generation sequencing technologies are making it practical and affordable to sequence the whole exome/genome of patients who display features suggestive of a genetic disorder. This approach enables the identification of smaller intragenic mutations including single-nucleotide variants that are not accessible even with high-resolution genomic array analysis. This article briefly summarizes the current status and achievements of the DECIPHER project and looks ahead to the opportunities and challenges of jointly analysing structural and sequence variation in the human genome.
患有发育障碍的患者通常存在亚显微缺失或重复,导致正常基因表达中断或剂量敏感基因拷贝数的改变。由于这些疾病的罕见性和新颖性,单独对这些患者进行临床解释受到阻碍。DECIPHER 项目(https://decipher.sanger.ac.uk)于 2004 年成立,作为一个可访问的基因组和相关表型数据在线存储库,其主要目标是帮助临床解释罕见的拷贝数变异(CNV)。DECIPHER 整合了来自各种生物信息学资源的信息,并使用可视化工具在 CNV 中识别潜在的疾病基因。两级访问系统允许临床医生和临床科学家为他们的患者维护具有机密链接的匿名表型和 CNV 记录,在获得知情同意后,这些记录可以与更广泛的临床遗传学和研究社区共享。下一代测序技术的进步使得对表现出遗传障碍特征的患者进行全外显子/基因组测序变得切实可行且负担得起。这种方法可以识别较小的基因内突变,包括即使使用高分辨率基因组阵列分析也无法获得的单核苷酸变异。本文简要总结了 DECIPHER 项目的现状和成就,并展望了联合分析人类基因组结构和序列变异的机遇和挑战。